With AbbVie Inc. not quite a year into US biosimilar competition to top-seller Humira, some shareholders’ thoughts apparently are turning to what is next for the large pharma, especially since the revenue paths for Humira post-US patent expiration and its successors Skyrizi and Rinvoq are in line or better than what was expected. Chairman and CEO Rick Gonzalez discussed succession plans for the top spot during AbbVie’s fourth quarter and full year 2023 sales and earnings call on 2 February.
AbbVie’s Gonzalez Outlines CEO Succession Process
Humira Erosion Follows Projections
AbbVie may look to an internal successor to Rick Gonzalez once he is satisfied the company is back on a growth trajectory. Skyrizi and Rinvoq continue meteoric growth, with increased sales projections.
More from Earnings
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024